NDAINTRAVENOUSSOLUTION
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
COMBOGESIC IV (acetaminophen and ibuprofen injection) by Hikma is cyclooxygenase inhibitors [moa]. Approved for nonsteroidal anti-inflammatory drug [epc]. First approved in 2023.
Drug data last refreshed 5h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBOGESIC IV is a fixed-dose combination of acetaminophen and ibuprofen administered intravenously for pain management and anti-inflammatory indications. The product combines two cyclooxygenase inhibitors to deliver rapid onset analgesia in the acute care setting. It represents a novel IV formulation approved in October 2023 targeting perioperative and hospital-based pain control.
Growth9.3 years to LOE
Early-stage growth product with limited competitive pressure, suggesting opportunity for market development teams to establish formulary positioning and hospital adoption networks.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COMBOGESIC IV represents a rare opportunity to build a product from market entry through growth phase with zero incumbents and no immediate generic threat. Career advancement potential is significant for professionals in commercial, market access, and hospital sales roles seeking visibility and impact on a growing franchise.
Brand Manager
Worked on COMBOGESIC IV at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.